Migraine News and Research

Latest Migraine News and Research

New investigational treatment may help prevent involuntary outbursts in MS and ALS patients

Pseudobulbar affect (PBA) is a neurologic condition of involuntary, sudden and frequent episodes of laughing or crying and is quite common in patients with underlying neurologic diseases or injuries, especially those with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

15 Apr 2010

GBS cases reduce following 2009 H1N1 vaccination: Research study

A new study finds that reports of a neurologic disease called Guillain-Barré syndrome have been low after 2009 H1N1 vaccination, according to a research study that will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

15 Apr 2010

Researchers identify gene that appears to increase risk of Alzheimer's disease

Researchers have identified a gene that appears to increase a person's risk of developing late-onset Alzheimer's disease, the most common type of Alzheimer's disease. The research will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

15 Apr 2010

52% migraine sufferers found relief from headache with Aspirin: review

Nearly 9 million people in UK suffer from debilitating headaches called migraine and this leads to a severe impairment in quality of life and affects productivity. The headaches associated with an attack may last for several days often bringing nausea and a general feeling of uneasiness in presence of lights and sounds.

15 Apr 2010

Aspirin can reduce acute migraine attacks

A single dose of 900-1000 mg aspirin can substantially reduce migraine headache pain within two hours, for more than half of people who take it. It also reduces any associated nausea, vomiting, and sensitivity to light or sound (photophobia or phonophobia).

15 Apr 2010

Anticonvulsants increase suicide risk

Dr. Elisabetta Patorno, a research fellow at Brigham and Women's Hospital and Harvard Medical School in Boston has published a study this week in the Journal of American Medical Association which found that taking anticonvulsant drugs raise thoughts of suicide and risks of actually trying to commit suicide by two times the norm. The study was sponsored by the Harvard School of Public Health and HealthCore, a research subsidiary of WellPoint. WellPoint is a health benefits company that serves the Blue Cross Blue Shield network.

14 Apr 2010

Benefits of moderate alcohol drinking on stroke risk counteracted by cigarette smoking

New research finds any beneficial effect of drinking moderate amounts of alcohol on stroke may be counteracted by cigarette smoking, according to research that will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

13 Apr 2010

New driving guideline for people with Alzheimer's disease

The American Academy of Neurology has issued a new guideline to help determine when people with Alzheimer's disease or another type of dementia should stop driving. The guideline is published in the April 12, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology, and was presented at the American Academy of Neurology's Annual Meeting in Toronto.

13 Apr 2010

Uninsured migraine sufferers likely to get inadequate treatment: Neurology

People with no health insurance are less likely than the privately insured to receive proper treatment for their migraines, according to a study published in the April 13, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

13 Apr 2010

Increase in circulating stem cells can be achieved through Stem-Kine: Study

A study published in the peer reviewed Journal of Translational Medicine demonstrated administration of Stem-Kine, a commercially available nutritional supplement, significantly elevated levels of two types of stem cells in circulation.

13 Apr 2010

Health care experts brand plan for a “Big Australia” as disaster waiting to happen

Increased immigration rates are set to make Australia’s population hit 36 million by the year 2050 according to Federal Government estimates. This would be a huge leap from the present 22,300,000 people that the nation has today. The added population is being seen as a necessity to ensure economical survival for the country.

13 Apr 2010

XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting

XenoPort announced today that new data from clinical trials of its product candidates arbaclofen placarbil and XP13512 (gabapentin enacarbil) will be presented at the 62nd Annual American Academy of Neurology meeting in Toronto, Ontario.

12 Apr 2010

People without migraines can filter out more visual noise: Study

When people feel the onset of a migraine headache, they may head to a dark, quiet room to rest. This instinct may be sound: A new study suggests that even without the headache, migraine sufferers may process visual cues better in an environment with few visual distractions.

12 Apr 2010

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.

8 Apr 2010

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

MAP Pharmaceuticals, Inc. today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX™ orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography.

8 Apr 2010

MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

MAP Pharmaceuticals, Inc. today announced the Company will present additional post-hoc analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy in two patient subpopulations that are often difficult to treat with current triptan migraine therapies: menstrual migraine and migraine with allodynia.

7 Apr 2010

2010 Internal Medicine conference at Toronto Convention Center

More than 5,000 internists (adult medicine specialists), subspecialists, medical students, and allied health professionals will meet in Toronto, Canada, for Internal Medicine 2010, the annual scientific meeting of the American College of Physicians (ACP), April 22 - 24 (Thursday - Saturday), at the Toronto Convention Center.

2 Apr 2010

Strong demand leads to 5.1% growth in 2009 U.S. sales of ethical pharmaceuticals

IMS Health today reported 5.1 percent growth in 2009 U.S. sales of ethical pharmaceuticals and insulins through retail and non-retail channels, reaching $300.3 billion, compared with growth of 1.8 percent in 2008.

2 Apr 2010

Lifetime Television to feature XenaCare Holdings' OTC pain reliever Cobroxin

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be featured on a segment of The Balancing Act, a morning show that airs on the top-rated women's cable television network, Lifetime Television.

1 Apr 2010

Conventional analgesics to drive acute pain market over the next decade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2018, the launches and uptake of reformulations of conventional analgesics will drive annual three percent growth in the acute pain drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

1 Apr 2010